The Phototransduction Pathway

Vishanna Balbirsingh

Phototransduction is the process by which light stimuli are converted into electrical signals in the retina, enabling vision. This biochemical cascade allows photoreceptor cells—rods and cones—to detect light, initiate electrical signalling, and ultimately send this information to the brain for visual perception.

Disruptions in these pathways, whether in the phototransduction process or in the recycling mechanisms, can lead to various visual disorders. Mutations in genes responsible for phototransduction and its components often result in retinal diseases, such as retinitis pigmentosa and congenital stationary night blindness. This paper will explore the phototransduction pathway, the recycling of visual pigments, and common gene mutations associated with retinal diseases.

The Phototransduction Pathway

The process of phototransduction begins when light enters the eye and is absorbed by photopigments within the photoreceptor cells in the retina. Photoreceptors are specialized cells that convert light into electrical signals. There are two main types of photoreceptors: rods and cones. Rods are highly sensitive to light and responsible for vision in dim light, whereas cones are responsible for colour vision and work best in bright light.

The core of phototransduction involves photopigments, which are composed of a light-sensitive chromophore (usually 11-cis retinal) and a protein called opsin. Each type of photoreceptor has its own opsin molecule. When light strikes the photopigment, it causes a conformational change in the chromophore from 11-cis retinal to all-trans retinal, initiating the phototransduction cascade.

Step-by-Step Process of Phototransduction (1)

  1. Photon Absorption: Phototransduction begins when a photon of light is absorbed by the photopigment in the outer segment of the photoreceptor. This absorption causes the 11-cis retinal chromophore to isomerize into all-trans retinal. The change in the chromophore’s structure triggers a conformational change in the opsin protein.
  2. Activation of Transducin: The activated opsin protein interacts with a G-protein called transducin. The transducin protein is a heterotrimeric G-protein consisting of three subunits: alpha, beta, and gamma. Upon activation, the alpha subunit of transducin exchanges GDP for GTP, and this GTP-bound alpha subunit dissociates from the beta and gamma subunits.
  3. Activation of Phosphodiesterase (PDE): The GTP-bound alpha subunit of transducin activates phosphodiesterase (PDE), an enzyme that hydrolyses cyclic GMP (cGMP). In the dark, cGMP levels are high and maintain the open state of cGMP-gated ion channels in the photoreceptor membrane, allowing sodium and calcium ions to flow into the cell. When PDE is activated, cGMP levels fall, causing the cGMP-gated ion channels to close.
  4. Hyperpolarization of the Photoreceptor: The closing of the cGMP-gated channels leads to a decrease in the influx of sodium and calcium ions, causing the photoreceptor membrane to hyperpolarize. This change in the photoreceptor’s membrane potential reduces the release of the neurotransmitter glutamate at the synapse with bipolar cells. The reduced glutamate release signals the presence of light.
  5. Signal Transmission to Bipolar Cells: The decrease in glutamate release activates on-bipolar cells and inhibits off-bipolar cells, leading to the transmission of visual information to the next layer of retinal neurons. From here, the signal is sent to retinal ganglion cells, which transmit visual information to the brain through the optic nerve.

Turning off the cascade

To turn off the phototransduction cascade, the photoreceptor cell must return to its baseline, dark-adapted state after light stimulation. This involves deactivating the key components of the signalling cascade to stop the hyperpolarization and reset the system.

  1. Rhodopsin Inactivation: Light activation of rhodopsin causes its conformational change, but to stop signalling, rhodopsin must be inactivated. Rhodopsin kinase (GRK) phosphorylates the activated rhodopsin, and this phosphorylated form binds to arrestin, preventing further activation of transducin, a G-protein.
  2. Deactivation of Transducin: The alpha subunit of transducin, when activated by rhodopsin, activates phosphodiesterase (PDE), which lowers cGMP levels. To switch off the cascade, GTPase-activating proteins (GAPs) accelerate the hydrolysis of GTP to GDP on transducin, turning it off. This deactivates PDE, halting the breakdown of cGMP.
  3. Restoration of cGMP Levels: With PDE turned off, guanylate cyclase synthesizes cGMP, which reopens the cGMP-gated ion channels (allowing sodium and calcium ions to enter). This restores the cell’s depolarized state.
  4. Resetting the Photoreceptor: The influx of ions through the open channels restores the photoreceptor to its dark current (depolarized state), and glutamate release is restored, signalling that the phototransduction cascade has been switched off and the system is ready for the next light stimulus.

Gene Mutations and Associated Diseases

Despite the efficiency of the phototransduction pathway and the recycling of visual pigments, gene mutations can disrupt these processes, leading to retinal diseases. Many of these mutations affect key components involved in phototransduction or visual pigment regeneration. Some of the most common gene mutations and their associated diseases include:

  1. Retinitis Pigmentosa (RP): Retinitis pigmentosa is a group of genetic disorders that cause progressive degeneration of the retina, particularly the rods, leading to night blindness and peripheral vision loss. RP can result from mutations in over 60 different genes. Some of the most common mutations are found in the RHO gene (which encodes rhodopsin, the opsin in rods), the PDE6A and PDE6B genes (which encode the alpha and beta subunits of phosphodiesterase), and the RPGR gene (associated with X-linked RP). These mutations disrupt the normal functioning of photoreceptors, impairing the phototransduction cascade and leading to vision loss (2–5).
  2. Congenital Stationary Night Blindness (CSNB): CSNB is a group of disorders that impair vision in low light but do not result in progressive retinal degeneration. It is often caused by mutations in the GRK1 gene (encoding G-protein-coupled receptor kinase 1), which is involved in the inactivation of rhodopsin after light activation (6). Without proper inactivation of opsin, photoreceptor cells cannot properly respond to light, leading to night blindness. Mutations in other genes, such as RHO and PDE6, can also cause CSNB (7).
  3. Leber Congenital Amaurosis (LCA): LCA is a severe form of retinal degeneration present from birth, leading to profound vision impairment. LCA can be caused by mutations in over 20 genes, including those involved in phototransduction (e.g., RPE65, which is involved in the regeneration of 11-cis retinal) and visual pigment recycling (8). RPE65 mutations impair the ability of the retinal pigment epithelium to regenerate visual pigments, resulting in early-onset blindness.
  4. Cone-Rod Dystrophy: Mutations in genes such as CNGA3 and CNGB3, which encode components of the cyclic nucleotide-gated ion channels in cones, can cause cone-rod dystrophy (9). This condition leads to loss of cone function (colour vision) followed by degeneration of rods, resulting in progressive loss of vision. Mutations in these genes disrupt the proper functioning of photoreceptors, particularly in response to light stimuli.

Conclusion

Phototransduction is a critical process for vision, converting light into electrical signals in the retina. The recycling of visual pigments, particularly through the activity of the retinal pigment epithelium, ensures that photoreceptors are continuously prepared to detect light. However, mutations in genes encoding key components of the phototransduction pathway or pigment regeneration process can lead to various retinal diseases, such as retinitis pigmentosa, congenital stationary night blindness, and Leber congenital amaurosis. Understanding these pathways and the genetic mutations that affect them provides valuable insights into both the molecular mechanisms of vision and the potential for developing therapeutic strategies to treat retinal diseases.

References

1. Lamb TD, Pugh EN. Phototransduction, Dark Adaptation, and Rhodopsin Regeneration The Proctor Lecture. Investig Opthalmology Vis Sci [Internet]. 2006 Dec 1 [cited 2024 Dec 18];47(12):5138. Available from: http://iovs.arvojournals.org/article.aspx?doi=10.1167/iovs.06-0849

2. Hashem SA, Georgiou M, Fujinami-Yokokawa Y, Laich Y, Daich Varela M, De Guimaraes TAC, et al. Genetics, Clinical Characteristics, and Natural History of PDE6B-Associated Retinal Dystrophy. Am J Ophthalmol [Internet]. 2024 Jul [cited 2024 Dec 18];263:1–10. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0002939424000552

3. Hashem SA, Georgiou M, Wright G, Fujinami-Yokokawa Y, Laich Y, Daich Varela M, et al. PDE6A-Associated Retinitis Pigmentosa, Clinical Characteristics, Genetics, and Natural History. Ophthalmol Retina [Internet]. 2024 Aug [cited 2024 Dec 18];S2468653024004056. Available from: https://linkinghub.elsevier.com/retrieve/pii/S2468653024004056

4. Nguyen XTA, Talib M, van Schooneveld MJ, Brinks J, Ten Brink J, Florijn RJ, et al. RPGR-Associated Dystrophies: Clinical, Genetic, and Histopathological Features. Int J Mol Sci. 2020 Jan 28;21(3):835.

5. Yan Z, Yao Y, Li L, Cai L, Zhang H, Zhang S, et al. Treatment of autosomal dominant retinitis pigmentosa caused by RHO-P23H mutation with high-fidelity Cas13X in mice. Mol Ther – Nucleic Acids [Internet]. 2023 Sep [cited 2024 Dec 18];33:750–61. Available from: https://linkinghub.elsevier.com/retrieve/pii/S2162253123002123

6. Poulter JA, Gravett MSC, Taylor RL, Fujinami K, De Zaeytijd J, Bellingham J, et al. New variants and in silico analyses in GRK1 associated Oguchi disease. Hum Mutat [Internet]. 2021 Feb [cited 2024 Dec 18];42(2):164–76. Available from: https://onlinelibrary.wiley.com/doi/10.1002/humu.24140

7. Zeitz C, Gross AK, Leifert D, Kloeckener-Gruissem B, McAlear SD, Lemke J, et al. Identification and Functional Characterization of a Novel Rhodopsin Mutation Associated with Autosomal Dominant CSNB. Investig Opthalmology Vis Sci [Internet]. 2008 Sep 1 [cited 2024 Dec 18];49(9):4105. Available from: http://iovs.arvojournals.org/article.aspx?doi=10.1167/iovs.08-1717

8. Thompson DA, Gyürüs P, Fleischer LL, Bingham EL, McHenry CL, Apfelstedt-Sylla E, et al. Genetics and phenotypes of RPE65 mutations in inherited retinal degeneration. Invest Ophthalmol Vis Sci. 2000 Dec;41(13):4293–9.

9. Thiadens AAHJ, Roosing S, Collin RWJ, Van Moll-Ramirez N, Van Lith-Verhoeven JJC, Van Schooneveld MJ, et al. Comprehensive Analysis of the Achromatopsia Genes CNGA3 and CNGB3 in Progressive Cone Dystrophy. Ophthalmology [Internet]. 2010 Apr [cited 2024 Dec 18];117(4):825-830.e1. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0161642009010008

Leave a Reply